Abstract
Ergot is commonly supposed to produce a powerful and persistent contraction of blood vessels. This belief rests mainly on clinical evidence, which is not conclusive; even when the observations are correct, they generally admit of other explanations. For instance, the hemostatic action of ergot in postpartum hemorrhage is now referred to the contraction of the uterine muscle, rather than to a vasoconstriction. It is also generally assumed that the vasoconstriction has been firmly established by experimental evidence. An inspection of any of the critical text-books of pharmacology, however, will suffice to show that different investigators have obtained variable results on mammals. This caused us to undertake the present investigation, the original object of which was to determine, on dogs, the circulatory effects of the ergot preparations as found on the market, in therapeutic doses, normally and in the pathologic conditions in which the drug is recommended. We intended to use
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
